Liquid Dosage
With diabetes on the rise and the global insulin market estimated to be worth more than $32 billion by 2018, demand for GEA technologies for the production of this life-saving drug is already high and set to increase, particularly in new markets and emerging economies.
GEA produces and supplies process systems for the production of liquid products for the pharmaceutical and biotechnological industries, and has a proven history of successfully installing plant for the production of insulin, including the engineering, delivery, commissioning and qualification of entire ultra-pure media systems as well as various process equipment and cleaning installations.
A worldwide technology leader in insulin production, GEA is able to supply the clean utility systems and manage the integration of all the main processes, including fermentation, harvesting, chromatography, filtration and freeze drying.
The biosynthetic production of human insulin is done using bacteria or yeast cells. Following fermentation, or the conversion of chemical raw materials by micro-organisms, the biomass is extracted using a nozzle separator, washed, concentrated and finally precipitated to produce insulin crystals.
Centrifuges and process lines provided by GEA have an established pedigree in the clarification, separation, classification, concentration and fractionation steps. Nozzle separators also play an important part in the production process. Further, GEA chamber or self-cleaning separators can be used in the subsequent crystallization stages.
GEA is a single-source supplier of a variety of fermenters, media preparation, buffer storage, harvesting and cell rupture solutions, equipment for the purification and isolation of cells, separation (after both first and final crystallization), the production and distribution of WFI, CIP and freeze drying technologies, all of which can be installed and integrated into a state-of-the-art insulin production facility.
Showing 4 of 14
Aseptic valves face exceptionally high demands within UltraClean and Aseptic processes. You can be assured that they all provide highest quality in terms of hygienic design and sustainability.
GEA separators are designed for liquid-based applications. Using centrifugal force, they are used for separating suspensions consisting of two or more phases of different densities, i.e. they can be used for liquid-liquid separation, for liquid-liquid-solid separation or for liquid-solid separation. They are equally as effective at separating liq...
Innovative CIP concepts of GEA meet comprehensive high standards. Our experts guarantee product safety at every point of the process. Every upgrade is adapted to individual local conditions and customer requirements and leads to noticeable savings.
GEA compression heads are the homogenizer pulsing core since they activate the homogenization process pumping the product at high pressure until it flows inside the homogenizing valve.
Whether it’s a fad or the future, 100% vial traceability is becoming an increasingly important consideration in the pharmaceutical freeze drying industry. Keeping a close eye on developments is GEA. We’re investigating possible solutions and, what’s more, we have the experience, expertise and know-how to implement them.
There was a time when the phrases ‘non-alcoholic beer’ and ‘tastes good’ were seldom used together in the same sentence, particularly by consumers. But low-proof and alcohol-free beers have come a long way – many of them now refreshing drinks in their own right – thanks in no small part to technology from GEA.
At GEA, our commitment to engineering for a better world fuels our pursuit of innovative solutions that enhance patient care and safety. One of our most promising ventures in recent years is aseptic spray drying – a technology that promises to revolutionize pharmaceutical manufacturing.